Sage Rhino Capital LLC recently announced the acquisition of new stake in Vincerx Pharma Inc (NASDAQ:VINC). The institutional investor has increased its shareholding in the Healthcare company by 0.98% to 1.7 million shares with purchase of 16476.0 shares. This fresh investment now brings its stake to 7.97% valued currently at $1.11 million. In addition, BofA Securities, Inc. raised its holdings by 1.45 million to 1.45 million shares.
With over 23.17 million Vincerx Pharma Inc (VINC) shares trading Monday and a closing price of $1.36 on the day, the dollar volume was approximately $31.52 million. Currently, there are 21.24M common shares owned by the public and among those 13.41M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 54,276 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Vincerx Pharma Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.33 million shares of the company’s stock, all valued at over $0.22 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.43% of the shares outstanding.
Shares of Vincerx Pharma Inc (NASDAQ: VINC) opened at $1.635, up $0.46 from a prior closing price of $1.18. However, the script later moved the day high at 1.7100, up 15.25%. The company’s stock has a 5-day price change of 15.25% and 36.00% over the past three months. VINC shares are trading 15.25% year to date (YTD), with the 12-month market performance up to 32.04% higher. It has a 12-month low price of $0.61 and touched a high of $1.95 over the same period. VINC has an average intraday trading volume of 74.61K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 59.90%, 66.56%, and 26.37% respectively.
Institutional ownership of Vincerx Pharma Inc (NASDAQ: VINC) shares accounts for 50.11% of the company’s 21.24M shares outstanding. Mutual fund holders own 30.75%, while other institutional holders and individual stakeholders account for 46.97% and 3.14% respectively.
It has a market capitalization of $29.08M and a beta (3y monthly) value of 0.09. The earnings-per-share (ttm) stands at -$2.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.84% over the week and 14.01% over the month.
Analysts forecast that Vincerx Pharma Inc (VINC) will achieve an EPS of -$0.37 for the current quarter, -$0.19 for the next quarter and -$0.58 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.44 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.65 a year ago. Earnings per share for the fiscal year are expected to increase by 34.41%, and 50.49% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Vincerx Pharma Inc (VINC) as a “Strong Buy” at a consensus score of 1.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the VINC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 14, 2022, with the firm’s price target at $25.
